The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact on second-line treatment after failure of immune checkpoint inhibitor (ICI) combination chemotherapy in extensive-disease small cell lung cancer: Experience of the Okayama Lung Cancer Study Group.
 
Yuka Kato
Speakers' Bureau - Chugai Pharma
 
Taku Noumi
No Relationships to Disclose
 
Kazuhiko Saeki
No Relationships to Disclose
 
Kiichiro Ninomiya
No Relationships to Disclose
 
Toshio Kubo
No Relationships to Disclose
 
Masanori Fujii
No Relationships to Disclose
 
Kammei Rai
No Relationships to Disclose
 
Eiki Ichihara
Honoraria - Boehringer Ingelheim (Inst); Lilly Japan (Inst); MSD (Inst); Nippon Kayaku (Inst)
Speakers' Bureau - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; MSD; Ono Yakuhin; Pfizer; Taiho Oncology
Research Funding - Janssen (Inst); MSD (Inst); Ono Yakuhin (Inst); Takeda (Inst)
 
Kadoaki Ohashi
No Relationships to Disclose
 
Masahiro Tabata
No Relationships to Disclose
 
Katsuyuki Hotta
No Relationships to Disclose
 
Toshiyuki Kozuki
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; Merck; MSD; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Kyowa-Hakko Kirin (Inst); Merck (Inst); MSD (Inst); Taiho Pharmaceutical (Inst)
 
Yoshinobu Maeda
Honoraria - Astellas Pharma; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Kyowa Kirin; Nippon Shinyaku; Takeda
Speakers' Bureau - Mundipharma; Pfizer
 
Katsuyuki Kiura
Speakers' Bureau - AstraZeneca Japan; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Chugai Pharma; Daiichi Sankyo; Lilly Japan; MSD; Novartis; Ono Yakuhin; Pfizer; Taiho Oncology
Research Funding - Novartis (Inst); Takeda (Inst)